CERo Therapeutics Holdings, Inc..
CERO.US | Research and experimental development on natural sciences and engineering
CERo Therapeutics Holdings, Inc. is a biotechnology company focused on the development of novel immunotherapies for cancer. The company's primary focus is on developing cell-based therapies that harness the power of the immune system to target and destroy cancer cells. Their research and development...Show More
Better Health for All
30
CERo Therapeutics has not yet commercialized any products and reported a net loss of $7.3 million in 2023, indicating no revenue from products with direct health impacts.
1
As a biotechnology company solely focused on developing next-generation engineered T cell therapeutics for cancer treatment, 100% of its R&D budget is dedicated to improving health outcomes. The company is conducting a first-in-human, multi-center, open-label Phase 1/1b clinical study for CER-1236, which includes dose escalation to determine the highest tolerated dose and an expansion phase to evaluate safety and efficacy.
2
Fair Money & Economic Opportunity
0
No evidence available to assess CERo Therapeutics Holdings, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
The company has no documented regulatory actions, violations, fines, or compliance issues related to labor laws or human rights in the provided articles.
1
No specific data is available for living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, insecure contract share, or health insurance coverage.
2
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence was found in the provided articles to assess CERo Therapeutics Holdings, Inc. against any of the KPIs for Fair Trade & Ethical Sourcing. discusses general industry trends and does not provide company-specific data.
1
refers to Cero Generation Limited, which is a different entity from CERo Therapeutics Holdings, Inc.
2
Honest & Fair Business
0
No evidence available to assess CERo Therapeutics Holdings, Inc. on Honest & Fair Business.
Kind to Animals
0
CERo Therapeutics uses animal models for preclinical testing of its cancer treatment, CER-1236, which demonstrated effectiveness in killing ovarian cancer cells in these models.
1
The company plans to initiate clinical trials for CER-1236 in early 2025.
2
However, the provided articles do not contain specific quantitative data or detailed policy information for any of the animal welfare KPIs, such as the number of animals used, alternative testing methods employed, or any certifications related to cruelty-free practices or humane operations.
No War, No Weapons
0
No evidence available to assess CERo Therapeutics Holdings, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, concrete data points for CERO.US were found in the provided articles for any of the Planet-Friendly Business KPIs. The articles primarily discuss industry-wide trends and statistics for the broader biotech and pharma sectors, rather than company-specific performance or disclosures. Therefore, no KPIs can be scored based on the evidence provided.
Respect for Cultures & Communities
0
No evidence available to assess CERo Therapeutics Holdings, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess CERo Therapeutics Holdings, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
The provided articles do not contain specific quantitative data or concrete facts for CERO.US regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability scores, waste audit frequency, zero-waste certifications, waste disposal violations, material efficiency, packaging-to-product ratios, waste reduction targets, supplier waste requirements, or customer waste education.
1